Inogen, Inc. (INGN)
Automate Your Wheel Strategy on INGN
With Tiblio's Option Bot, you can configure your own wheel strategy including INGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INGN
- Rev/Share 13.5095
- Book/Share 7.8663
- PB 0.839
- Debt/Equity 0.0971
- CurrentRatio 3.0665
- ROIC -0.1311
- MktCap 177455520.0
- FreeCF/Share -0.7586
- PFCF -9.2957
- PE -6.043
- Debt/Assets 0.0623
- DivYield 0
- ROE -0.1476
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INGN | B. Riley Securities | -- | Buy | -- | $14 | June 16, 2025 |
| Upgrade | INGN | Needham | Hold | Buy | -- | $12 | May 22, 2025 |
News
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Read More
3 Stocks With Upgraded Broker Ratings to Bet on Amid Uncertainties
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Broker upgrades boost URBN, INGN and SWX, with earnings growth and strong Zacks Ranks signaling potential upside despite market volatility.
Read More
Inogen Upgraded: Analyst Sees Growth, EBITDA Breakthrough
Published: May 22, 2025 by: Benzinga
Sentiment: Positive
Needham analyst Mike Matson upgraded Inogen, Inc INGN from Hold to Buy, with a price forecast of $12.
Read More
What Makes Inogen (INGN) a New Buy Stock
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
After Plunging -15.69% in 4 Weeks, Here's Why the Trend Might Reverse for Inogen (INGN)
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Negative
Inogen (INGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.
Read More
Inogen, Inc. (INGN) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Inogen, Inc. (NASDAQ:INGN ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - CFO Conference Call Participants Colin Clark - Stifel Mike Matteson - Needham & Company Margaret Andrew - William Blair Operator Welcome to Inogen's First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Read More
Here's What Key Metrics Tell Us About Inogen (INGN) Q1 Earnings
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.62 per share a year ago.
Read More
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.
Read More
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid fourth-quarter 2024 performance and a strong product portfolio, seems justified.
Read More
Inogen, Inc. (INGN) Q4 2024 Earnings Call Transcript
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Inogen, Inc. (NASDAQ:INGN ) Q4 2024 Earnings Conference Call February 25, 2025 5:00 PM ET Company Participants Ryan Peterson – Investor Relations Kevin Smith – President and Chief Executive Officer Mike Bourque – Chief Financial Officer Conference Call Participants Operator Welcome to Inogen's Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Read More
Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Inogen (INGN) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $1.14 per share a year ago.
Read More
About Inogen, Inc. (INGN)
- IPO Date 2014-02-14
- Website https://www.inogen.com
- Industry Medical - Devices
- CEO Mr. Kevin R. M. Smith
- Employees 766